Neoplasms

Heart and Blood Diseases

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Rare Diseases

Multiple Myeloma

Neoplasms, Plasma Cell

Neoplasms by Histologic Type

Hemostatic Disorders

Blood Coagulation Disorders

Vascular Diseases

Paraproteinemias

Blood Protein Disorders

Hematologic Diseases

Hemorrhagic Disorders

Lymphoproliferative Disorders

Immunoproliferative Disorders

PRLX 93936 administered IV 3 days a week (Monday, Wednesday and Friday) for 3 weeks followed by a 9 day rest period = 1 cycle

PRLX 93936 administered IV 3 days a week (Monday, Wednesday and Friday) for 3 weeks followed by a 9 day rest period = 1 cycle, multiple cycles may be administered

PRLX 93936

Amy Destefanis

Robert Schlossman, MD

Barbara Riff

Katherine McKernan

Peter Voorhees, MD

Kimberly Oates

Cristina Gasparetto, MD

Sue O'Gara

John Morris, MD

Cindy Farley

Jesus G. Berdeja, MD

Paul Richardson, MD

To determine the maximum tolerated dose of, and response to, PRLX 93936 as treatment for patients with relapsed or relapsed/refractory multiple myeloma.

* To determine the maximum tolerated dose (MTD) and the dose limiting toxicities (DLT) of PRLX 93936 administered IV 3 days a week (Monday, Wednesday and Friday) for 3 weeks followed by a 9 day rest period, as treatment for patients with relapsed or relapsed/refractory multiple myeloma.
* To establish the dose of PRLX 93936 recommended for future studies.
* To characterize potential toxicities of PRLX 93936.
* To assess the pharmacokinetic profile of PRLX 93936.
* To evaluate response to treatment, time to response (TTR) and duration of response.
* To evaluate time to progression (TTP).

Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma

Phase 1/2, Multi-center, Open Label, Dose Escalation, Safety, Efficacy and PK Study of PRLX 93936 Administered IV 3 Days a Week for 3 Weeks Followed by a 9 Day Rest Period in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

Prolexys Pharmaceuticals

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma	NCT01695590	Multiple Myelom...	PRLX 93936	18 Years -	Prolexys Pharmaceuticals
Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma	NCT01695590	Multiple Myelom...	PRLX 93936	18 Years -	Prolexys Pharmaceuticals

Spots Global Cancer Trial Database for prlx93936

Every month we try and update this database with for prlx93936 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for prlx93936

Every month we try and update this database with for prlx93936 cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for prlx93936 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.